NCT Number: NCT00330876
Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.
Looking for future studies?
Notify MeKey information
Conditions
Age range
65 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Copenhagen University Hospital, Copenhagen, Denmark
About this study
This was an open-label study of 60 weeks duration in elderly patients (≥65 years) with primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in study NK-104-306 and who met the inclusion/exclusion criteria. Patients who qualified started open-label treatment with pitavastatin 2 mg QD. The dose of pitavastatin could be increased to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain their LDL-C target.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Greater than or equal to 65 years of age
- Primary hypercholesterolemia
- Combined dyslipidemia
- Completed study NK-104-306 (NCT00257686)
Exclusion criteria
- Failed to complete study NK-104-306(NCT00257686)
Treatment and study plan
Primary outcomes
-
Change From Baseline in LDL-C
Time frame: Baseline to 60 weeks
percent change from baseline in low density lipoprotein-cholesterol (LDL-C)
Secondary outcomes
-
Change From Baseline in Total Cholesterol
Time frame: Baseline to 60 weeks
Percent change from baseline in total cholesterol (TC)
Sponsors and collaborators
Lead sponsor
Kowa Research Europe
Industry
Registry information
Official study title
Open-Label, Long-Term (> 1 Year) Extension Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Important dates
- Study start
- 2006
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- May 29, 2006
- Registry last updated
- Mar 16, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels
NCT05988866
Dyslipidemias, Hypercholesterolemia
Hamburg, Germany
View Trial DetailsDachundou No Sugar Added Soymilk for Lipid Modulation
NCT07175766
Cardiovascular Diseases, Dyslipidemias
Taoyuan, Taiwan
View Trial DetailsStudy of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597
ASCVD, Arterial Occlusive Diseases
Gilbert, Arizona, United States
View Trial DetailsRandomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722
Arterial Occlusive Diseases, Arteriosclerosis
Anniston, Alabama, United States
View Trial Details